Albain K S
Division of Hematology/Oncology, Loyola University Medical Center, Maywood, Illinois, USA.
Oncology (Williston Park). 1997 Sep;11(9 Suppl 9):51-7.
The objectives of this review are to provide an update and perspectives on the use of induction therapy (chemotherapy with or without radiotherapy) followed by surgery in two subgroups of patients with stage III non-small-cell lung cancer. The first subset is that of bulky stage IIIAN2 or IIIB disease (standard treatment: chemoradiotherapy), and the second, minimal stage IIIA non-N2 or computed tomography (CT)-negative N2 disease (standard therapy: initial surgical resection). Details of recent major trials in each of these two subsets are provided regarding selections criteria, study design, toxicity, resection rates, median and long-term survival, and predictors of survival. The review concludes with a discussion of whether consensus has emerged about the addition of surgery after induction chemoradiotherapy in the group with bulky disease and whether there should now be a standard recommendation for preoperative chemotherapy with or without radiotherapy in patients with initially resectable tumors.
本综述的目的是提供关于在Ⅲ期非小细胞肺癌两个亚组患者中先进行诱导治疗（化疗联合或不联合放疗）然后进行手术的最新情况和观点。第一个亚组是肿块型ⅢA N2期或ⅢB期疾病（标准治疗：放化疗），第二个亚组是微小ⅢA期非N2或计算机断层扫描（CT）阴性N2期疾病（标准治疗：初始手术切除）。针对这两个亚组中近期的主要试验，提供了关于选择标准、研究设计、毒性、切除率、中位生存期和长期生存率以及生存预测因素的详细信息。综述最后讨论了对于肿块型疾病组在诱导放化疗后加用手术是否已达成共识，以及对于最初可切除肿瘤的患者现在是否应该有术前化疗联合或不联合放疗的标准推荐。
